Bio Pharma Dive
FEBRUARY 28, 2022
The findings build on early evidence that gene editing inside the body could safely and effectively treat disease, and suggest the effects of Intellia's medicine might last.
World of DTC Marketing
FEBRUARY 28, 2022
Advertising is meant to “sell” your product, but the pharma industry is unique because people don’t just see an ad for a prescription drug and run to their doctor. There is a path between awareness and asking for/receiving an Rx. It’s more than just about understanding; it’s about being relevant to the needs of online health seekers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 2, 2022
Amazon’s encroachment into healthcare advanced a little further this week when the online giant launched a doctor consultation service delivered via its Alexa voice assistant, with the help of telehealth player Teladoc. Users of the service will be able to request non-urgent medical care around the clock, simply by telling Alexa via their Amazon Echo device that they want to speak to a doctor.
BioPharma Reporter
FEBRUARY 28, 2022
Medicago and GlaxoSmithKline (GSK) have gained approval for Covifenz, the companiesâ plant-based COVID-19 vaccine, from Health Canada.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
FEBRUARY 28, 2022
The CAR-T treatment is the second to be approved in the U.S. for the blood cancer, following Bristol Myers Squibb and 2Seventy bio's Abecma.
World of DTC Marketing
MARCH 2, 2022
Over 73% of patients plan to continue using telemedicine platforms post-pandemic, according to Doximity’s second edition of its State of Telemedicine Repor t , which was released today. As part of the report, Doximity, the leading digital platform for U.S. medical professionals, analyzed the adoption of telemedicine across its physician user base from January 2020 through June 2021 and conducted a study of patients’ experiences with telemedicine during the same time frame.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
MARCH 3, 2022
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies to market more quickly.
Bio Pharma Dive
MARCH 1, 2022
Biotech CEOs Paul Hastings and Jeremy Levin explained the goals behind a letter supported by more than 400 executives and investors that calls for drugmakers to stop working with Russian companies.
World of DTC Marketing
MARCH 1, 2022
The United States accounts for more than 40% of global health spending. Hea Healthcarending made up 5% of total U.S. GDP in 1960. In 020, spending hit almost 20% of total U.S. GDP. It’s a significant issue, but healhealthcare companies are determined to record profits. Americans aren’t using more health care than people in other nations that spend less.
pharmaphorum
FEBRUARY 28, 2022
UK Health Secretary Sajid Javid has said he wants to accelerate the rollout of electronic patient records (EPR) in the NHS, with 90% of NHS trusts using them by the end of 2023. Javid laid out the new target in a speech to the HSJ Digital Transformation Summit, in which he said that current estimates are that one in five NHS trusts still do not have EPR, and so are missing out on a key technology to deliver better, safer care for patients.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
MARCH 2, 2022
MS patients given boost by results of study into Kesimpta – a self-administered treatment with potential to improve lives
Bio Pharma Dive
MARCH 3, 2022
Biogen confirmed that some of its U.S. employees have been informed their roles are being eliminated. It's unclear, though, the magnitude of the layoffs or which departments are most affected.
World of DTC Marketing
MARCH 3, 2022
Press Ganey recently asked1 1,000+ healthcare consumers about their digital behaviors, but unfortunately, their findings mean little to emarketers working within the industry. They are somewhat embarrassing. So let’s look at some of the top insights from the report, along with my snide comments: Consumers turn to pharma sites for reliable information: In the age of empowered consumers, access to reliable healthcare information has never been more demand.
BioPharma Reporter
MARCH 1, 2022
The authors of clinical data published in Nature Medicine this week said the findings indicate the use of a live biotherapeutic (LBP) with immunotherapy medicine can improve survival in patients with metastatic kidney cancer.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MARCH 2, 2022
There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. Ben Hargreaves discovers why medical research in the area has shifted from being highly controversial to being backed by major pharma companies and venture capital. The image of psychedelic drugs within medical research is changing.
Bio Pharma Dive
FEBRUARY 28, 2022
Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies.
Scienmag
MARCH 2, 2022
Abrupt shifts in the evolution of animals – short periods of time when an organism rapidly changes size or form – have long been a challenge for theorists including Darwin. Now a newly published research paper supports the idea that even these abrupt changes are underpinned by a gradual directional process of successive incremental changes, […].
XTalks
MARCH 3, 2022
In the perfect food industry merger and acquisition (M&A) deal, both parties come out ahead. Last year saw several examples of both buyers and sellers in the food industry walking away with something to position them for more stable, sustainable growth. But which countries had the most food industry M&A deals in 2021? US Leads Food Industry M&A Deals.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MARCH 3, 2022
Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 da
Bio Pharma Dive
MARCH 3, 2022
As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for TEKTURNA+HCT Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Noden Pharma drug TEKTURNA HCT appeared first on DrugPatentWatch - Make Better Decisions.
JAMA Internal Medicine
FEBRUARY 27, 2022
This randomized clinical trial assesses whether Mindfulness-Oriented Recovery Enhancement is more efficacious than supportive group psychotherapy for reducing opioid misuse among adults with chronic pain receiving long-term opioid therapy.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioPharma Reporter
MARCH 3, 2022
WuXi STA says its drug product facility in Wuxi City, China has successfully passed its first pre-approval inspection (PAI) and received the GMP compliance certificate from the European Medicines Agency (EMA).
Bio Pharma Dive
MARCH 3, 2022
While a stock market slide has made IPOs difficult for young biotech companies, venture capital firms like Atlas are still reloading with new cash to create and invest in new drugmakers.
XTalks
MARCH 3, 2022
Food allergies are becoming more and more common, but that doesn’t mean those with allergies can’t enjoy a sweet treat. In this episode of the Xtalks Food Podcast, Sydney talks about Partake Foods, an allergen-friendly, better-for-you snack brand that offers cookies, baking mixes and other products in which everyone can partake. However, the brand sells more than just sweet treats.
pharmaphorum
FEBRUARY 28, 2022
A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common “mass market” conditions. The analysis by IQVIA and pharma company Chiesi looked at the per patient, per year (PPPY) direct, indirect and mortality-related costs associated with 24 rare diseases, and compared them to 24 chronic ailments like diabetes, heart disease, arthritis and cancers.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Channels
MARCH 1, 2022
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
Bio Pharma Dive
MARCH 3, 2022
The nonprofit group announced ambitious plans to begin offering insulin at prices no higher than $30 per vial by early 2024.
XTalks
FEBRUARY 28, 2022
Today is Rare Disease Day, which is celebrated annually on the rarest day of the year, February 28 (or February 29 in leap years). Rare Disease Day is a global movement that strives to foster equity in access to diagnosis, care and therapies, as well as social opportunity for people with rare diseases. The theme of this year’s Rare Disease Day is “Share Your Colours,” which is a call to shine light on individuals with rare diseases to hear about their stories, experiences and aspirations.
pharmaphorum
FEBRUARY 28, 2022
Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing application for Oleogel-S10, its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL) from the FDA emerged, with the agency asking for “additional confirmatory evidence of effectiveness” for cutaneous manifestations of dystrophic and junctional EB.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
344 
Let's personalize your content